Depomed (NASDAQ: DEPO) reported Q2 EPS of $0.27, $0.27 better than the analyst estimate of $0.00. Revenue for the quarter came in at $94.3 million versus the consensus estimate of $88.33 million.

Depomed sees FY2015 revenue of $320-340 million, versus prior guidance of $335-310 million. The company sees adjusted earnings of $40 - $50 million, from prior expectations of $16 - 28 million.

For earnings history and earnings-related data on Depomed (DEPO) click here.

Earnings Guidance Hot Guidance

Janney Capital Downgrades DepoMed Inc (DEPO) to NeutralJuly 30, 2015 9:28 AM RBC Capital Downgrades DepoMed Inc (DEPO) to Sector PerformJuly 30, 2015 6:46 AM Depomed (DEPO) Board Rejects Horizon Pharma's (HZNP) Revised Takeover ProposalJuly 29, 2015 4:05 PM Depomed Reports Record Sales and Cash Flow in Second Quarter 2015 and Raises Full Year 2015 GuidanceJuly 29, 2015 4:04 PM Depomed's Board of Directors Unanimously Rejects Purported Revised, Highly Conditional, Unsolicited Proposal from Horizon Pharma plcJuly 29, 2015 4:03 PM Depomed to Report Second Quarter Fiscal Year 2015 Financial Results on Wednesday, July 29, 2015July 29, 2015 8:00 AM